Study wrapper · #175
Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.
Editor's note
This systematic review and network meta-analysis (41 RCTs, 2,906 participants) compares antidiabetic drugs' effects on body composition — fat mass and lean body mass. Among incretin therapies, tirzepatide showed the greatest fat-mass reduction versus placebo (MD −10.70 kg), ahead of semaglutide and liraglutide; but it was also associated with the largest lean-mass reduction (MD −4.40 kg). That dual finding is the substantive contribution: the potent fat loss from GIP/GLP-1 agonism comes with meaningful lean-mass loss, and the review notes exercise mitigated liraglutide-related lean-mass loss. Network meta-analyses allow indirect comparisons across trials but rest on assumptions of transitivity and consistency, and the total sample is modest with likely heterogeneity in how body composition was measured. Consistent with growing attention to muscle preservation during rapid weight loss, weigh this as useful comparative evidence on composition — while remembering that lean-mass change is not equivalent to functional or clinical outcomes, which the analysis does not assess.
Plain-language abstract
This review combined 41 randomised trials (about 2,906 people) to compare how different diabetes medications change body composition — specifically fat mass and lean (muscle) mass. Using a method that lets researchers compare drugs indirectly across trials, they found that among the GLP-1 and dual GIP/GLP-1 medications, tirzepatide produced the largest reduction in fat mass (about 10.7 kg more than placebo), followed by liraglutide combined with exercise; semaglutide and liraglutide produced moderate reductions. However, tirzepatide was also linked to the largest loss of lean muscle mass (about 4.4 kg), and liraglutide caused smaller muscle loss — though adding exercise reduced that muscle loss. Some other drug types (like SGLT2 inhibitors) had only small effects, while metformin, insulin, and certain others had little impact. The authors note that these powerful weight-loss drugs reduce fat effectively but also reduce muscle, and they call for more research on dosing, treatment length, and the role of lifestyle.